- Home
- COOK vs GHRS Comparison
COOK vs GHRS Comparison
Compare COOK & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOK
- GHRS
- Stock Information
- Founded
- COOK 1985
- GHRS 2018
- Country
- COOK United States
- GHRS Ireland
- Employees
- COOK N/A
- GHRS N/A
- Industry
- COOK Wholesale Distributors
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- COOK Consumer Discretionary
- GHRS Health Care
- Exchange
- COOK Nasdaq
- GHRS Nasdaq
- Market Cap
- COOK 255.1M
- GHRS 925.2M
- IPO Year
- COOK 2021
- GHRS 2021
- Fundamental
- Price
- COOK $1.96
- GHRS $15.58
- Analyst Decision
- COOK Buy
- GHRS Strong Buy
- Analyst Count
- COOK 7
- GHRS 8
- Target Price
- COOK $2.43
- GHRS $30.63
- AVG Volume (30 Days)
- COOK 318.2K
- GHRS 187.7K
- Earning Date
- COOK 08-05-2025
- GHRS 09-02-2025
- Dividend Yield
- COOK N/A
- GHRS N/A
- EPS Growth
- COOK N/A
- GHRS N/A
- EPS
- COOK N/A
- GHRS N/A
- Revenue
- COOK $602,441,000.00
- GHRS N/A
- Revenue This Year
- COOK $0.06
- GHRS N/A
- Revenue Next Year
- COOK $3.18
- GHRS N/A
- P/E Ratio
- COOK N/A
- GHRS N/A
- Revenue Growth
- COOK 0.80
- GHRS N/A
- 52 Week Low
- COOK $1.28
- GHRS $6.00
- 52 Week High
- COOK $3.97
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- COOK 61.44
- GHRS 67.14
- Support Level
- COOK $1.85
- GHRS $14.20
- Resistance Level
- COOK $1.98
- GHRS $15.54
- Average True Range (ATR)
- COOK 0.10
- GHRS 1.07
- MACD
- COOK 0.01
- GHRS 0.29
- Stochastic Oscillator
- COOK 75.14
- GHRS 93.84
About COOK Traeger Inc.
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.